Research progress of immunogenic cell death in the immunotherapy of colorectal cancer
10.3781/j.issn.1000-7431.2023.2209-0624
- VernacularTitle:免疫原性细胞死亡在结直肠癌免疫治疗中的研究进展
- Author:
Donghao TANG
1
,
2
,
3
;
Jinbao CHEN
;
Jie WANG
Author Information
1. 上海中医药大学附属普陀医院普外科,上海 200062
2. 安徽医科大学第五临床医学院,安徽合肥 230032
3. 安徽医科大学上海普陀中心临床学院普外科,上海 200062
- Keywords:
Colorectal cancer;
Immunotherapy;
Immunogenic cell death
- From:
Tumor
2023;43(11):886-894
- CountryChina
- Language:Chinese
-
Abstract:
Colorectal cancer(CRC)is a common malignant tumor of the digestive system.The main treatments for CRC currently include surgical resection,chemotherapy,radiotherapy,and immunotherapy.Immunogenic cell death(ICD)is an important method ofanti-tumortherapy.ICD is a specific type of cell death that involves the release of damage-associated molecular patterns(DAMPs).These DAMPs can be effectively taken up by dendritic cells(DCs),neutrophils,and macrophages,thereby stimulating adaptive immune responses in the body.However,colorectal cancer is considered a"cold tumor"with relatively low immunogenicity,resulting in a low response rate to immunotherapy.Inducing ICD can potentially enhance the immunogenicity of colorectal cancer,leading to long-term tumor control.This review aims to explore the impact of ICD development in colorectal cancer treatment and investigate the potential of ICD inducers in colorectal cancer immunotherapy.
